Canopy Growth and Spectrum Therapeutics Expand Medical Portfolio with New 30 and 90-Pack Softgels and Enhanced Dosing Options

SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) and Spectrum Therapeutics today announced an expansion of its Minor Cannabinoid softgel lineup, introducing new 30 and 90-pack formats and additional dosing options across its Optimized Spectrum portfolio. The expansion builds on the strong performance of existing 30-pack formats and reflects Canopy Growth's ongoing commitment to improving patient access through targete.